FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:377-378 July 29, 1999 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Muennig, P. PubMed Citation

To the Editor: The conclusion by Muennig et al. (March 11 issue)¹ that empirical treatment of all U.S. immigrants at risk for parasitosis would result in a net health benefit is driven by the assumption in their decision-analysis model that albendazole has no serious side effects. The authors base this assumption on the seven field trials of albendazole that found no serious side effects requiring medical attention. However, these trials studied the use of albendazole in a total of fewer than 3000 patients. Most of the trials monitored patients for three weeks or less and relied principally on the patients' . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.